jose-manuel carrascosa

head of department, associated professor

Hospital Universitari Germans Trias i Pujol

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

José-Manuel Carrascosa is the Head of Department and Associate Professor at Hospital Universitari Germans Trias i Pujol in Spain. His research primarily focuses on dermatology, particularly the efficacy and safety of treatments for atopic dermatitis and psoriasis. His recent publications examine the impact of allergic comorbidities on treatment efficacy, the cardiovascular safety of psoriasis treatments, and the management of prurigo nodularis. He contributes significantly to understanding drug survival and adverse event risks associated with biologic agents in dermatological therapies.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (12)

Sergio Santos Alarcón

SPAIN

View details

Antonio Costanzo

Full Professor of Dermatology

Humanitas University

ITALY

View details

Mar Llamas‐Velasco

SPAIN

View details

Antonio J Garcia Ruiz

Profesor Titular de Universidad – TU/ Catedrático de Escuela Universitaria - CEU

University of Malaga

SPAIN

View details

Constanze Jonak

AUSTRIA

View details

Jose-Juan Pereyra-Rodriguez

SPAIN

View details

José C. Armario-Hita

Professor of Dermatology

Universidad de Cádiz

SPAIN

View details

Diamant Thaçi

University of Lübeck

GERMANY

View details

Julia-Tatjana Maul

University Hospital of Zurich

SWITZERLAND

View details

Peter Lio

UNITED STATES

View details

Alvaro Hidalgo

Profesor Titular de Universidad

University of Castilla-La Mancha

SPAIN

View details

Leopoldo Borrego

Professor

Universidad de Las Palmas de Gran Canaria

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

jose-manuel carrascosa

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?

Cardiovascular safety of systemic psoriasis treatments: A prospective cohort study in the BIOBADADERM registry

Clinical Characteristics, Diagnostic Approaches, Therapeutic Management, and Associated Comorbidities of Prurigo Nodularis (Chronic Nodular Prurigo): An Observational Study in Clinical Practice in Spain

Comprehensive Literature Review Evaluating the Use, Safety, and Efficacy of Subcutaneous Methotrexate in the Treatment of Adult Patients With Moderate‐To‐Severe Plaque‐Type Psoriasis

Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis: An international, real‐world comparative study

Risk of adverse events of psoriasis treatment with biologic agents and new small molecules—BIOBADADERM Registry

Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicentre retrospective study

Lebrikizumab Improved Itch Symptoms and Reduced Itch Interference on Sleep over 52 Weeks in Patients with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials

Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of Life

Tratamiento tópico de la psoriasis: recomendaciones de expertos del Grupo Español de Psoriasis (GPS)

Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: a systematic literature review

Apremilast treatment of plaque psoriasis (PsO) after systemic therapy in Spanish clinical practice: Data from the APPROPRIATE study

No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: Multicenter case series of 35 patients

Assessing the value of moderate‐to‐severe atopic dermatitis treatment using multi‐criteria decision analysis (MCDA)

No impact of disease duration on response to tildrakizumab treatment among patients with moderate‐to‐severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies

Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate‐to‐severe plaque psoriasis patients in conditions close to clinical practice

Conventional therapy in psoriasis. Lost in translation?

Allergic contact dermatitis to alkyl glucosides: Epidemiological situation in Spain

Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis.

Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group

Collaborators (12)

Sergio Santos Alarcón

Antonio Costanzo

Mar Llamas‐Velasco

Antonio J Garcia Ruiz

Constanze Jonak

Jose-Juan Pereyra-Rodriguez

José C. Armario-Hita

Diamant Thaçi

Julia-Tatjana Maul

Peter Lio

Alvaro Hidalgo

Leopoldo Borrego

Make your next move.